Centrosomes, which mediate accurate chromosome segregation during mitosis, undergo duplication precisely once per cell division at the G 1 /S boundary. Recently, we described centrosome aberrations as a possible cause of aneuploidy in acute myeloid leukemia (AML) and found a correlation of the percentage of cells carrying abnormal centrosomes to their cytogenetic risk profile. To elucidate the molecular events responsible for the development of centrosome aberrations in AML, tumor RNA of 29 AML samples was hybridized to cDNA microarrays. The microarrays comprised some 2800 different genes with relevance to hematopoiesis, tumorigenesis and mitosis and included a set of 359 centrosome-associated genes. We identified two gene expression signatures, which allowed an accurate classification according to the extent of centrosome aberrations and the ploidy status in 28 of 29 patients each. Specifically, 18 genes were present in both signatures, including genes that code for cell cycle regulatory proteins (cyclin A2, cyclin D3, cyclin H, CDK6, p18 INK4c , p21
Cip1 , PAK1) and centrosome-associated proteins (pericentrin, a2-tubulin, NUMA1, TUBGCP2, PRKAR2A). In conclusion, the high expression of centrosome-associated genes matches the description of centrosome aberrations in several tumor types. Moreover, in AML the identification of G 1 /S-phase stimulatory genes suggests that one mechanism of aneuploidy induction might be the deregulation of centrosome replication at the G 1 /S boundary. Keywords: centrosome aberrations; aneuploidy; numerical chromosome changes; acute myeloid leukemia Faithful segregation of chromosomes into daughter cells is essential for maintaining the genetic stability of most organisms. Chromosome segregation is mediated by the mitotic spindle (Hartwell and Kastan, 1994; Nicklas, 1997; Waters and Salmon, 1997) . Although it is not completely understood how spindles are assembled, the centrosome plays an important role in this process (Merdes and Cleveland, 1997; Waters and Salmon, 1997) . The centrosome needs to be duplicated exactly once per cell cycle. Recently, it has been demonstrated that centrosome duplication in somatic cells is controlled by the phosphorylation status of the retinoblastoma (RB) protein, release of the transcription factor E2F from RB binding and subsequent activation of cyclin-dependent kinase (CDK) 2 in the late G 1 -phase (Hinchcliffe et al., 1999; Lacey et al., 1999; Meraldi et al., 1999) .
Genetic instability is a common feature of malignant neoplasias. It is frequently characterized by numerical chromosome abnormalities, a condition known as aneuploidy. Furthermore, recent results demonstrate that aneuploid cells exhibit continuous changes in chromosome number throughout their lifetime, suggesting that this chromosome instability may contribute to tumor progression (Lengauer et al., 1997; Kramer et al., 2002) . Defects in chromosome number are thought to occur through missegregation of chromosomes (Hartwell and Kastan, 1994; Lengauer et al., 1997) , but the exact mechanism is not understood. However, many recent studies provided evidence that centrosome aberrations result in chromosome missegregation and may lead to malignant transformation and tumor progression (Zhou et al., 1998; Carroll et al., 1999; Marx, 2001 ).
Recently, we described centrosome aberrations as a possible cause of aneuploidy in acute myeloid leukemia (AML) and found a correlation of the percentage of cells carrying abnormal centrosomes to their cytogenetic risk profile . Since neither the mechanisms leading to centrosome aberrations nor the contribution of defective centrosomes to the acquisition of karyotype abnormalities is understood in AML, we analysed the expression profile of 29 AML specimens using cDNA-based microarrays. The microarrays comprised some 2800 different genes with relevance to hematopoiesis, tumorigenesis and mitosis and included a set of 359 centrosome-associated genes, which were selected as described in Figure 1 .
All AML samples were characterized by cytogenetic studies and immunostaining of centrosomes using a centrosome-specific antibody to pericentrin (Table 1) as described previously . In comparison to 21 AML patients with normal chromosome count, the extent of centrosome aberrations was higher in eight AML patients with numerical chromosome changes (32.078.4% versus 48.379.8%, Po0.001). To analyse whether numerical chromosome changes of AML patients are characterized by specific gene expression signatures, we used the nearest shrunken centroid classification for statistical analysis (Tibshirani et al., 2002) , which identifies minimal combinations of genes that provide a signature for the best discrimination between two known patient groups. We identified a set of 52 genes, which allowed an accurate classification of AML patients with respect to the ploidy status in 28 of 29 cases (Figure 1) .
To assess the results of the microarray data in further detail, 12 of 52 genes listed in Figure 1 (CAMK1, CCND3, CDC25C, CDK6, CHK2, DNCLI2, NPM1, NUMA1, PCNT2, PLK, PRKAR2A, TUBGCP2) were randomly chosen for further quantitative analysis using RQ-PCR. RQ-PCR analysis was performed in six euploid as well as in six aneuploid leukemia samples, harboring 33.3710.3 and 51.4710.9% of cells with centrosome abnormalities (P ¼ 0.01), respectively. Consistent with the results obtained by microarray experiments for the total group of 29 AML samples, DNCLI2 (401-fold), CCND3 (71-fold), PRKAR2A (33-fold) and NUMA1 (10-fold) were found to be expressed at high levels in these 12 AML samples by RQ-PCR as compared to the reference RNA, whereas CHK2, CDK6 and CDC25C were expressed at lower levels. All 12 genes analysed by RQ-PCR displayed higher expression levels in aneuploid versus euploid AML patients, confirming the results obtained by microarray analysis. More detailed information concerning primer sequences, RQ-PCR conditions and results can be found at the following URL address: http://www.dkfz.de/ kompl_genome/Other/primer_sequences.zip
To obtain a significant set of genes separating patients with high and low numbers of centrosome aberrations, shrunken centroid classification was used in a two-step approach as described in Figure 2 . We identified a set of 21 genes, which allowed an accurate classification of AML patients with respect to the numbers of centrosome aberrations in 28 of 29 cases (Figure 2) . The identified gene expression signature includes genes with relevance to centrosome structure and function (NUMA1, PRKAR2A, TUBA2, TUBGCP2, PCNT2) as well as genes that are involved in the replication cycle of centrosomes (CCNA2, CCND2, CCND3, CCNH, CDK6, CDKN2C, CDKN1A, MAPK3, MCM2, MCM5, MCM7, PAK1, RAD51L1, RBBP2, TP53BP1, YWHAH).
When the two gene expression signatures describing ploidy status (Figure 1 ) and centrosome aberrations ( Figure 2 ) were compared, a common set of 18 genes was present in both the gene expression signatures for ploidy status and centrosome aberration levels, encoding either cell cycle regulatory proteins (cyclin A2, cyclin D3, cyclin H, CDK 6, p18
, p21/CDC42/ RAC1-activated kinase 1, RB binding protein 2), centrosome-associated proteins (pericentrin, a2-tubulin, nuclear mitotic apparatus protein NUMA, TUBGCP2, PRKAR2A) or proteins required for DNA replication (MCM2, MCM5, MCM7, RAD51L1, p53-binding Figure 1 Supervised hierarchical clustering analysis of differentially expressed genes according to the ploidy status, including eight aneuploid and 21 euploid AML samples. The genes were selected by the nearest shrunken centroid classification that identifies minimal combinations of genes for the best discrimination between two known patient groups (Tibshirani et al., 2002) . The microarrays contain replicate spots of 4628 different gene-specific fragments, representing some 2440 different genes selected on the basis of their relevance to hematopoiesis (Stratowa et al., 2001 ) and tumorigenesis (Korshunov et al., 2003) as described previously. In addition, 359 genes were selected, which code for proteins that are associated with centrosomes (CAM kinases, pericentrin, g-tubulin, 76P, GCP2, GCP3, CEP1, CEP2, centrin, cullin, katanin, dynein, polo, aurora, TACC, RANBP, nucleophosmin, ninein, NUMA, NEK, PKA, CDC14) or proteins that are involved in the replication/duplication of centrosomes: in particular in cell cycle control (cyclins, CDKs, CDK inhibitors), G 2 /M-phase checkpoints (ATM, CHK2, BUB1), DNA repair (XRCC2, XRCC3, BRCA1, BRCA2), p53 and RB with downstream effectors/regulators (MDM2, p21
Waf/Cip1 , GADD45, E2F), mitotic regulation (STK15/BTAK, securin, survivin) and genome damage-signaling (ATR). Information about centrosome-associated genes was acquired from recent publications. Subsequently, the corresponding cDNA-clones were ordered from German Resource Center for Genome Research (Berlin, Germany). The RNA of leukemic samples was hybridized with commercially available universal human reference RNA (Stratagene, La Jolla, USA), composed of total RNA from ten human cancer cell lines. cDNA-microarray experiments were performed as described previously by our group . Briefly, approximately 1 mg of leukemia and 1 mg of reference mRNA were labeled with Cy3 and Cy5, respectively, using the Omniscript Reverse Transcriptase kit (QIAGEN) and hybridized with 10 mg CotI DNA, 30 mg bovine liver tRNA and 10 mg oligo-dT nucleotides in an automated hybridization chamber (GeneTac; Genomic Solutions). A color switch experiment was performed for each AML sample, where the leukemia and reference DNA was labeled via Cy3-and Cy5-dUTP, respectively, and vice versa. For image analysis, GenePix Pro imaging software 4.0 (Axon Instruments, Inc.) was used. Individual data reports for all conducted experiments were exported and further analysed using the R software environment for statistical computing (http://www.r-project.org). Data sets for spots not recognized by the GenePix analysis software were excluded from further considerations. Additionally, all remaining data sets were ranked according to spot homogeneity (as assayed by the ratio of median and mean fluorescence intensities), spot intensity and the standard deviation of log ratios for replicate spots. Those data points ranked among the lower 20%, based on the criteria just described, were removed from the data set. For each hybridization, fluorescence ratios (Cy5/Cy3) were normalized by variance stabilization (Huber et al., 2002) . To combine experiments with switched dye labeling, the ratios of one experiment were inverted and averaged with the corresponding spots on the second array We examined a set of 29 patients with AML, including 13 men and 16 women with a median age of 62 years (range, 26-80) . A total number of 20 patients was registered as having de novo AML, whereas nine patients with secondary AML were analysed. Analogous to the MRC-AML 10 trial (Grimwade et al., 1998) , the AML patients were classified according to their cytogenetic risk profile. For centrosome immunolabeling, cytospins were prepared and stained using a polyclonal antibody to pericentrin (Covance, Richmond, CA, USA) as described previously . Immunostaining of centrosomes was judged satisfactory when the characteristic single or paired centrosome pattern was detected in negative controls. Centrosomes were considered structurally abnormal if they had a diameter at least twice that of centrosomes in nonmalignant control cells and numerically abnormal if they were present in numbers 42. At least 200 consecutive cells per sample were carefully examined Centrosome aberrations in acute myeloid leukemia K Neben et al protein 1). Moreover, eight of these 18 genes code for proteins, namely cyclin A2, cyclin D3, cyclin H, p18 INK4C , MCM2, nuclear mitotic apparatus protein NUMA, PRKAR2A and RAD51L1, which were also among the genes initially found to be abundantly expressed (greater than twofold) in all 29 AML samples.
Recently, two studies showed that AML samples with normal karyotype or balanced reciprocal rearrangements t(8;21), t(15;17) and inv(16) can be distinguished by specific gene expression profiles (Schoch et al., 2002; Debernardi et al., 2003) . In line with Debernardi et al., we found that certain members of the class I homeobox A and B gene families are abundantly expressed in AML samples with normal karyotype (e. g. HOXA9, HOXB5 ). In addition, Virtaneva et al. (2001) compared AML samples with normal karyotype to cases with trisomy 8 as a sole abnormality and found that trisomy 8 is associated with a high expression of genes that are located on chromosome 8, suggesting a gene-dosis effect. These gene expression profiling studies were performed with the Affimetrix system (Virtaneva et al., 2001; Schoch et al., 2002; Debernardi et al., 2003) . In contrast, we used a 'centrosome-specific' cDNA-microarray for hybridization. Whereas these studies were designed to identify specific AML subsets by gene expression clustering, we focused on the molecular events responsible for the development of centrosome aberrations and numerical chromosome changes.
Among the structural centrosome proteins whose expression was found to be associated with both aneuploidy and high-level centrosome aberrations, TUBGCP2 codes for the g-tubulin complex associated protein 2 (GCP2), a major component of the g-tubulin Figure 2 Gene expression signature describing the extent of centrosome aberrations. To obtain a significant set of genes separating patients with high and low numbers of centrosome aberrations, shrunken centroid classification was used in a two-step approach (Tibshirani et al., 2002) . Based on the extent of centrosome aberrations, AML samples were divided into three subgroups, harboring low (o30%; n ¼ 8), intermediate (30-40%; n ¼ 12) and high percentages (440%; n ¼ 9) of aberrant cells. We assumed that the best classification in our sample set is achieved for the two subgroups displaying low and high percentages of cells with centrosome defects. The expression data were then used to generate a classifier that is able to differentiate both subgroups according to the extent of centrosome aberrations. This classifier was employed to assign each of the 12 AML patients with an intermediate level of aberrations to one of both subgroups. The extended subgroups displaying low (n ¼ 17; 29.878.0%) and high (n ¼ 12; 47.0710.9%) percentages of aberrant cells (Po0.001) were analysed a second time using nearest shrunken centroid classification to yield the specific gene expression signature for all 29 AML patients. A set of 21 genes allowed a correct classification of both subgroups except one patient who was classified wrongly. For each gene the mean expression in comparison to the reference RNA is shown ring complex that serves as a template for microtuble polymerization from closely related a-and b-tubulin. aTubulin is an integral part of the centrioles, the core components of centrosomes and forms together with its heterodimerization partner b-tubulin interphase and spindle microtubules. Overexpression of pericentrin has been reported to induce severe centrosome and spindle defects, cellular disorganization, genomic instability and enhanced growth in soft agar in prostate epithelial cell lines (Pihan et al., 2001) . Pericentrin, a large coiled-coil protein, serves as a scaffold that recruits g-tubulin ring complexes and several other centrosomeregulatory proteins to centrosomes in vertebrate cells (Dictenberg et al., 1998) . Thus, there might be a pathophysiological link between high expression levels of TUBGCP2 and the detection of centrosome aberrations by an antibody to pericentrin in our series of AML patients.
Centrosomes duplicate exactly once per cell cycle, thereby ensuring a strictly bipolar mitotic spindle axis. Duplication of the single centrosome is initiated at the G 1 /S transition of the cell cycle and completed before mitosis. Analogous to DNA replication, duplication of the centrosome is triggered by the phosphorylation status of the RB protein, release of the transcription factor E2F from RB binding and subsequent activation of CDK2/cyclin A or CDK2/cyclin E complexes in the late G 1 -phase of the cell cycle. Correspondingly, in AML samples with a high degree of centrosome aberrations, we found higher expression levels of genes coding for proteins involved in the stimulation of the G 1 /S transition and, thereby, centrosome replication, including G 1 cyclins (cyclin A2, cyclin D2, cyclin D3, cyclin H), cyclin-dependent kinases (CDK6), cyclin/ CDK assembly factors (p21
Cip1
) and RB-regulated transcription factors (RBBP2). Mammalian cells express two structurally redundant cyclin-D-dependent kinases (CDK4 and CDK6) and three redundant partner cyclins (cyclins D1-3), with predominant expression of CDK6/ cyclin D3 in hematopoietic cells (Chen et al., 2003) . Similar to CDK4 activity in mesenchymal cells, CDK6 activity seems to be required in hematopoietic cells for G 1 /S transition and inactivation of the RB protein by releasing RB-bound transcription factors like E2F, which we have found to be highly expressed in aneuploid AML samples as well (E2F6, RBBP2). Recent data indicate that p21
Cip1 acts as an assembly factor that is necessary for the binding of D-type cyclins to CDK4 and CDK6 and, thus, progression through the G 1 -phase (Cheng et al., 1999) . Cyclin A2, one of the two cyclins that activate CDK2, has been shown to be necessary not only for S-phase entry but also for initiation of centrosome replication at the G 1 /S boundary (Meraldi et al., 1999) . Cyclin A/CDK2 complex activation requires CDK2-activating kinase (CAK) consisting of CDK7 and cyclin H, yet cyclin H is one more cyclin regulating G 1 /S transition that we found abundantly expressed in centrosomal and chromosomal aberrant AML samples.
Taken together, we describe here comprehensive expression signatures of a set of selected genes associated with centrosome aberrations and numerical chromosome abnormalities in AML. The overexpression of proteins related to centrosome structure like gtubulin and pericentrin might have been expected from the description of centrosome aberrations by antibody staining against these proteins in several tumor types. However, the number of identified genes involved in the stimulation of the G 1 /S-phase transition suggests that at this critical point of the cell cycle not only progression towards DNA replication but indeed also centrosome duplication is controlled. Since centrosomal and chromosomal aberrations show an impact on the prognosis in AML, our identified gene expression signatures might be of prognostic relevance.
